Matches in SemOpenAlex for { <https://semopenalex.org/work/W1997437575> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1997437575 endingPage "130" @default.
- W1997437575 startingPage "130" @default.
- W1997437575 abstract "Osteoporosis has become an important health problem in postmenopausal Asian populations as the prevalence of hip and vertebral fractures in some Asian countries has risen to approach that of Caucasian populations. Risedronate, a pyridinyl-bisphosphonate agent, is a potent inhibitor of bone resorption. Risedronate increases bone mineral density (BMD), reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. To determine the efficacy and tolerability of risedronate in Chinese, a multicenter, randomized, double blind, placebo controlled study was performed in Hong Kong. Sixty-five (65) postmenopausal osteoporotic Southern Chinese women, aged 67 ± 6 years, were randomly assigned to receive either risedronate 5 mg daily (n = 31) or placebo (n = 34) for 12 months. All women received calcium carbonate 500 mg daily and vitamin D 400 IU daily. Mean baseline BMD T-score at the spine and total hip was −3.4 and −2.6, respectively. A significant increase in spine BMD was already evident at month 3 of risedronate treatment (P < 0.001). Risedronate significantly increased BMD and reduced bone turnover markers as compared with placebo. The risedronate group had significant increase in BMD at 12 months at both the spine and hip when compared with the placebo group (L1–4 6.6% vs. 0.4%, P < 0.001; total hip 2.7% vs. 0.3, P < 0.0001; femoral neck 1.8% vs. 1.1%, P < 0.02; trochanter 4% vs. 1.1%, P < 0.0001, respectively). Significant changes in urine N-telopeptide (NTx) and serum osteocalcin were evident as early as 1 and 3 months, respectively, with risedronate treatment. No significant changes were seen in both BMD and bone markers in the placebo group. Risedronate was well tolerated without major adverse effects. We conclude that risedronate is an effective and well-tolerated agent for the treatment of postmenopausal osteoporosis in Asian population." @default.
- W1997437575 created "2016-06-24" @default.
- W1997437575 creator A5006460186 @default.
- W1997437575 creator A5014817898 @default.
- W1997437575 creator A5019619605 @default.
- W1997437575 creator A5031978220 @default.
- W1997437575 creator A5032362473 @default.
- W1997437575 creator A5038185936 @default.
- W1997437575 creator A5049442593 @default.
- W1997437575 creator A5089627406 @default.
- W1997437575 date "2008-04-01" @default.
- W1997437575 modified "2023-10-18" @default.
- W1997437575 title "Accuracy of MRI in predicting pathologic residual disease after neoadjuvant chemotherapy" @default.
- W1997437575 doi "https://doi.org/10.1016/s1359-6349(08)70591-3" @default.
- W1997437575 hasPublicationYear "2008" @default.
- W1997437575 type Work @default.
- W1997437575 sameAs 1997437575 @default.
- W1997437575 citedByCount "0" @default.
- W1997437575 crossrefType "journal-article" @default.
- W1997437575 hasAuthorship W1997437575A5006460186 @default.
- W1997437575 hasAuthorship W1997437575A5014817898 @default.
- W1997437575 hasAuthorship W1997437575A5019619605 @default.
- W1997437575 hasAuthorship W1997437575A5031978220 @default.
- W1997437575 hasAuthorship W1997437575A5032362473 @default.
- W1997437575 hasAuthorship W1997437575A5038185936 @default.
- W1997437575 hasAuthorship W1997437575A5049442593 @default.
- W1997437575 hasAuthorship W1997437575A5089627406 @default.
- W1997437575 hasConcept C126322002 @default.
- W1997437575 hasConcept C126894567 @default.
- W1997437575 hasConcept C141071460 @default.
- W1997437575 hasConcept C142724271 @default.
- W1997437575 hasConcept C170033053 @default.
- W1997437575 hasConcept C197934379 @default.
- W1997437575 hasConcept C204787440 @default.
- W1997437575 hasConcept C27081682 @default.
- W1997437575 hasConcept C2775854910 @default.
- W1997437575 hasConcept C2776541429 @default.
- W1997437575 hasConcept C2776886416 @default.
- W1997437575 hasConcept C2777251235 @default.
- W1997437575 hasConcept C2778375690 @default.
- W1997437575 hasConcept C2781104859 @default.
- W1997437575 hasConcept C71924100 @default.
- W1997437575 hasConceptScore W1997437575C126322002 @default.
- W1997437575 hasConceptScore W1997437575C126894567 @default.
- W1997437575 hasConceptScore W1997437575C141071460 @default.
- W1997437575 hasConceptScore W1997437575C142724271 @default.
- W1997437575 hasConceptScore W1997437575C170033053 @default.
- W1997437575 hasConceptScore W1997437575C197934379 @default.
- W1997437575 hasConceptScore W1997437575C204787440 @default.
- W1997437575 hasConceptScore W1997437575C27081682 @default.
- W1997437575 hasConceptScore W1997437575C2775854910 @default.
- W1997437575 hasConceptScore W1997437575C2776541429 @default.
- W1997437575 hasConceptScore W1997437575C2776886416 @default.
- W1997437575 hasConceptScore W1997437575C2777251235 @default.
- W1997437575 hasConceptScore W1997437575C2778375690 @default.
- W1997437575 hasConceptScore W1997437575C2781104859 @default.
- W1997437575 hasConceptScore W1997437575C71924100 @default.
- W1997437575 hasIssue "7" @default.
- W1997437575 hasLocation W19974375751 @default.
- W1997437575 hasOpenAccess W1997437575 @default.
- W1997437575 hasPrimaryLocation W19974375751 @default.
- W1997437575 hasRelatedWork W1978798479 @default.
- W1997437575 hasRelatedWork W2029256459 @default.
- W1997437575 hasRelatedWork W2111972076 @default.
- W1997437575 hasRelatedWork W2113159741 @default.
- W1997437575 hasRelatedWork W2139080121 @default.
- W1997437575 hasRelatedWork W2355684772 @default.
- W1997437575 hasRelatedWork W2474502010 @default.
- W1997437575 hasRelatedWork W2492519731 @default.
- W1997437575 hasRelatedWork W2982378025 @default.
- W1997437575 hasRelatedWork W58560150 @default.
- W1997437575 hasVolume "6" @default.
- W1997437575 isParatext "false" @default.
- W1997437575 isRetracted "false" @default.
- W1997437575 magId "1997437575" @default.
- W1997437575 workType "article" @default.